99 0

Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells

Title
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Author
김용희
Keywords
Nano-immunotherapeutic; Tumor microenvironmental immune cells-targeted cancer immunotherapy; Tumor-associated macrophage-targeted nano-immunotherapeutics; Tumor-infiltrating T cell-targeted nano-immunotherapeutics; Tumor-associated dendritic cell-targeted nano-immunotherapeutics
Issue Date
2019-10
Publisher
ELSEVIER SCI LTD
Citation
BIOMATERIALS, v. 219, article no. UNSP 119401
Abstract
The tumor microenvironmental immune cells (TMICs) consists of myeloid cells (tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells, etc.) and lymphocytes (T cells and B cells), all of which could be immunologically suppressed through their interactions with cancer cells. Immunological understanding of the tumor microenvironment (TME) has led to great success in the development of clinical cancer immunotherapeutic. The most advanced cancer immunotherapies are chimeric antigen receptor-modified T cells (CAR-T cells) and checkpoint inhibiting antibodies blocking CTLA4, PD-1 and PD-L1. However, many hurdles remain that should be addressed for improved therapeutic efficacy and reduced side effects such as cytokine release syndrome and patient-death. In recent decades, nanoparticles have been demonstrated as an efficient drug delivery tool due to their ease of modification, biocompatibility and intrinsic tumor targeting effect, and also been applied for cancer immunotherapy. In this review, we briefly introduce the immunosuppressive functions of TMICs and review recent advances in the development of TMIC-targeted nanotherapeutics for cancer immunotherapy. Tumor-associated macrophage (TAM)-targeted systems have shown to deplete or re polarize macrophages to M1 state for anti-tumoral immune responses. Tumor-infiltrating T cell (TIT)-targeted strategies have provided the activation of effector T cells and suppression of regulatory T cells in tumor, overcoming the current hurdles of single regimen checkpoint inhibitors. Lastly, recent studies on dendritic cell-targeted mRNA vaccination are discussed and the future perspectives of nano-immunotherapeutic for next-generation of cancer immunotherapy is emphasized.
URI
https://www.sciencedirect.com/science/article/pii/S0142961219305009?via%3Dihubhttps://repository.hanyang.ac.kr/handle/20.500.11754/152038
ISSN
0142-9612; 1878-5905
DOI
10.1016/j.biomaterials.2019.119401
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE